(NASDAQ: MAZE) Maze Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.27%.
Maze Therapeutics's earnings in 2026 is -$122,542,000.On average, 12 Wall Street analysts forecast MAZE's earnings for 2026 to be -$156,588,347, with the lowest MAZE earnings forecast at -$182,783,259, and the highest MAZE earnings forecast at -$127,847,553. On average, 12 Wall Street analysts forecast MAZE's earnings for 2027 to be -$186,137,182, with the lowest MAZE earnings forecast at -$244,072,601, and the highest MAZE earnings forecast at -$147,318,016.
In 2028, MAZE is forecast to generate -$222,532,225 in earnings, with the lowest earnings forecast at -$320,548,683 and the highest earnings forecast at -$165,620,694.